Compounding Draft Guidance May End Par's Suit Against US FDA

Par says FDA shouldn't have authorized a compounded version of Vasostrict, but parties have asked court to wait until March, when a guidance is expected that may resolve the company's concerns.

Pharmacistswithmortatandpestle_1200x675

The US FDA may resolve Endo Pharmaceuticals Inc.'s lawsuit challenging the agency's drug compounding policy through draft guidance set to be released in March.

The parties filed a Jan. 24 joint motion to stay the case until either March 30 or the occurrence...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership